Quarterly ResultMay 7, 2026, 11:16 AM
Genmab Q1 Revenue +25% to $896M; Net Profit $53M
AI Summary
Genmab reported a 25% increase in Q1 2026 revenue to $896 million, primarily driven by higher DARZALEX and Kesimpta royalties and increased EPKINLY net product sales. However, net profit significantly decreased by 73% to $53 million, largely due to acquisition and integration-related charges and net financial items. The company also received FDA approval to remove the 24-hour hospitalization recommendation for EPKINLY in certain DLBCL patients and maintained its full-year 2026 financial guidance.
Key Highlights
- Revenue increased 25% to $896 million in Q1 2026 from $715 million in Q1 2025.
- Net profit decreased 73% to $53 million in Q1 2026 from $195 million in Q1 2025.
- Royalty revenue rose 26% to $742 million, driven by DARZALEX ($562M) and Kesimpta ($116M).
- Global net sales of EPKINLY/TEPKINLY grew 52% to $137 million.
- Operating expenses, excluding acquisition charges, increased 25% to $606 million.
- FDA approved sBLA to remove 24-hour hospitalization for EPKINLY in relapsed/refractory DLBCL.
- Maintained 2026 full-year revenue guidance of $4.065-$4.395 billion.